Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

CytRx to Present at the Marcum MicroCap Conference



  CytRx to Present at the Marcum MicroCap Conference

Business Wire

LOS ANGELES -- May 23, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, announced that President and CEO Steven A.
Kriegsman will present at the 2^nd Annual Marcum MicroCap Conference on
Thursday, May 30, 2013, at 10:00 a.m. Eastern time (7:00 a.m. Pacific time).
The conference is being held at the Grand Hyatt hotel in New York City.

A webcast of the presentation will be available on the Company’s website at
http://cytrx.com/investors/presentations.

The Marcum MicroCap Conference will allow institutional investors, sell-side
analysts and investment bankers the opportunity to consider the investment
prospects being showcased by the next generation of up-and-coming microcap
companies in seven industries, including Life Sciences. The conference is
expected to draw more than 1,000 attendees. Marcum LLC is one of the largest
independent public accounting and advisory services firms in the nation.
Marcum is a member of the Marcum Group, an organization providing a
comprehensive range of professional services spanning accounting and advisory,
technology solutions, wealth management, and executive and professional
recruiting.

About CytRx Corporation

The CytRx oncology pipeline is focused on the clinical development of
aldoxorubicin (formerly known as INNO-206), its improved version of the widely
used chemotherapeutic agent doxorubicin. CytRx has initiated an international
Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed
its Phase 1b/2 clinical trial primarily in the same indication, and has
initiated a Phase 1b pharmacokinetics clinical trial in patients with
metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination
with doxorubicin in patients with advanced solid tumors. The Company is
initiating an international Phase 3 pivotal trial under a special protocol
assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue
sarcomas whose tumors have progressed following treatment with chemotherapy.
CytRx is expanding its pipeline of oncology candidates based on a novel linker
platform technology that can be utilized with multiple chemotherapeutic agents
and could allow for greater concentration of drug at tumor sites. The Company
also has rights to two additional drug candidates, tamibarotene and bafetinib.
The Company completed its evaluation of bafetinib in the ENABLE Phase 2
clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and
plans to seek a partner for further development of bafetinib, and is
evaluating further development of tamibarotene. For more information about
CytRx Corporation, visit www.cytrx.com.

Contact:

Investor Relations
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
twagner@legendsecuritiesinc.com
or
CytRx Corporation
David Haen
Vice President, Business Development
310-826-5648 x304
dhaen@cytrx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement